| answer text |
<p>We are aware of a supply issue with glucagon-like peptide 1 receptor agonist (GLP-1
RA) medicines, including Ozempic pens. We have issued guidance in the form of Medicine
Supply Notifications and, on 18 July 2023, issued a National Patient Safety Alert
with advice for healthcare professionals on how to manage patients requiring this
medicine.</p><p>Our guidance is clear that GLP-1 RA medicines that are solely licensed
to treat Type 2 diabetes should only be used for that purpose and should not be routinely
prescribed for weight loss.</p><p>The General Pharmaceutical Council, General Medical
Council, Health and Care Professions Council, Nursing and Midwifery Council and Pharmaceutical
Society of Northern Ireland have also issued a joint statement stressing the importance
of health and care professionals meeting regulatory standards in relation to these
medicines. We have also added some of these products to the list of medicines that
cannot be exported from, or hoarded in, the United Kingdom.</p><p>We are continuing
to work closely with manufacturers and others working in the supply chain to help
ensure the continued supply of these medicines for UK patients, for example by asking
suppliers to expedite deliveries. We have provided advice for healthcare professionals
on how to manage patients requiring this medicine whilst there are shortages and are
keeping this under review as the situation evolves.</p>
|
|
